Tvm Med Serv S.R.L.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis4 trials
• Crohn's disease3 trials
• Coeliac disease1 trial

Phase

• Phase 25 trials
• Phase 33 trials
• Phase 2/31 trial

Status

• Recruiting5 trials
• Completed2 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial

Lead sponsor

• Hoffmann-La Roche2 trials
• Janssen Research & Development, LLC2 trials
• Spyre Therapeutics, Inc.2 trials
• AbbVie1 trial
• Can-Fite Biopharma Ltd.1 trial
• and 1 more

Running trials

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet

  2023-506150-21-00· Phase 2· Dr. Falk Pharma GmbH· Source

• Recruiting

  A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

  NCT04697810· Phase 2· Can-Fite Biopharma Ltd.· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Ulcerative colitis2 recruiting
• Coeliac disease1 recruiting

Closed trials

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source